门冬氨酸鸟氨酸注射液治疗肝硬化肝性脑病的疗效观察

目的探讨门冬氨酸鸟氨酸注射液治疗肝硬化肝性脑病的疗效。方法将92例肝硬化肝性脑病患者随机分为门冬氨酸鸟氨酸（10—20g加5％GS250ml，静脉滴注，1次／d），加常规治疗组（A组）和常规治疗组（B组），（支链氨基酸和乙酰谷酰胺），疗程皆为7d，观察治疗前后患者，临床症状和体征，检测治疗前后肝功能及血氨的变化，判断临床疗效。结果治疗后，A组中24h清醒36例，72h清醒40例，B组中24h，清醒22例，72h清醒34例，P〉0．05，A组血氨治疗前后分别为（110．30±33．4）μmol／1，（46．30±27．35）μmol／l。B组为（110．25±23．40）μmol／1，（63．21±21．91）μmol／l，A组治疗前后ALT分别为（298．61±325．15）U／L，（165．30±180．18）U／L，血清胆红素分别为：（278．01±185．21）μmol／1，（224．34±159．80）μmol／1（P〈0．01），B组血ALT治疗前后分别为（375．60±360．80）U／L（224．34±159．80）U／L，血清胆红素分别为（334．70±170．58）μ／1（279．60±167．17）μmol／l，（P〈0．01）。结论门冬氨酸鸟氨酸能有效降低血氨及胆红素，是控制肝性脑病的有效药物。

Clinical study of onithine-aspartate for treatment hepatic encephalopathy of liver cirrhosis

Objective To evaluate the efficacy of serum onithine asprartate for treatment bepatic encephalogpahty of liver cirrhosis.Methods 92 patients with hepatic encephalopathy of liver cirrhosis were devided into two groups,group A treated with onithine-aspartate and routine treatment,group (B)with routine treatment total course of treatment were 7 days,to observe patients clinic symptom and physical symptom the serum ammconia and other biological parameters were also determened subsequently before and ofter treatment.Results After treatment 36 cases were consaousness in 24 hours,40 cases were consciousness in 72 hours fromgroup A,22 cases were consciousness in 24 hours 34 cases were consciousness in 72 hours,from group B(P＞0.05).Serum ammconia in group A and group B whose before tneatment,and after treatment were(110.30 ±33.4)μmol/l,(46.30±27.35 ) μmol/1.B ( 110.25±23.40 )μmol/l,( 63.21±21.91 ) μmol/l,ALT in group A before and after treat ment were ( 298.61±325.15 ) U/L,( 165.30±180.18 ) U/L treat ment were ( 298.61±325.15 ) U/L,( 165.30 ±180.18) U/L whereas the serum total bilirubin in group A (278.01±185.21 ) μmol/1(224.34 ±159.80) μmol/l P ＜ 0.01 ALT in group B sefore and ter tretent were ( 375.60 ±360.8 ) mmol/l(224.34±159.80) U/L whereas the serum total bilirubin in goup B ( 334.70 ±170.58 ) μmol/l ( 279.60 ±167.17)μmol/l,P ＜0.01.Conclusion Onithine-aspartate can decrease the ammonia and total bilirubin sig nificantly onithine-aspartate is effective ontreating hepatic encephalopathy in patients with liver cirrhosis.